01:34 , Nov 1, 2012 |  BC Extra  |  Financial News

Synthetic Biologics raises $10.8 million

Synthetic Biologics Inc. (NYSE-M:SYN) raised about $10.8 million on Wednesday through the sale of about 6.8 million shares at $1.60 in a private placement to new and existing investors. The price is a 31% discount...
00:22 , Oct 30, 2012 |  BC Extra  |  Financial News

Synthetic Biologics to raise $10.9 million

Synthetic Biologics Inc. (NYSE-M:SYN) said it plans to raise about $10.9 million through the sale of 6.8 million shares at $1.60 in a private placement to new and existing investors. The price is a 31%...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Intrexon, Synthetic Biologics deal

Intrexon granted Synthetic Biologics (formerly Adeona Pharmaceuticals Inc. ) exclusive, worldwide rights to develop and commercialize mAbs for three undisclosed infectious disease indications using Intrexon's technologies. The deal includes Intrexon's UltraVector technology for assembling transgenes...
00:58 , Aug 9, 2012 |  BC Extra  |  Company News

Intrexon, Synthetic Biologics in infectious disease deal

Intrexon Corp. (Blacksburg, Va.) granted Synthetic Biologics Inc. (NYSE-M:SYN) exclusive, worldwide rights to develop and commercialize mAbs for three undisclosed infectious disease indications using Intrexon's technologies, including the UltraVector technology for assembling transgenes and its...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

Trimesta: Completed Phase II enrollment

Synthetic Biologics (formerly Adeona Pharmaceuticals Inc. ) completed enrollment of 164 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 8 mg Trimesta daily plus Copaxone glatimer acetate for 2 years. Teva Pharmaceutical Industries...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Adeona management update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Hired: C. Evan Bellantyne as CFO, formerly EVP and CFO of Clinical Data Inc. , which Forest Laboratories Inc. acquired; and Jeff Riley, chairman,...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Adeona management update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Hired: John Monahan as SVP of R&D, founder and formerly CEO of Avigen Inc. , which MediciNova Inc. acquired  ...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Adeona, Intrexon deal

Intrexon's Human Therapeutics Division granted Adeona exclusive, worldwide rights to develop and commercialize a DNA-based therapeutic to treat pulmonary arterial hypertension (PAH). The therapeutic uses Intrexon's UltraVector technology for assembling transgenes and its RheoSwitch Therapeutic...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Clinical News

Trimesta: Phase II started

Adeona began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate Trimesta in 64 relapsing-remitting or secondary-progressive female MS patients. The Skirball Foundation and Adeona will equally support the trial. Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Adeona board of directors update

Adeona Pharmaceuticals Inc. (NYSE-A:AEN), Ann Arbor, Mich.   Business: Autoimmune   Appointed: Jeff Riley as non-executive chairman; he succeeds James Kuo, who remains CEO, president and a director  ...